Lilly Needs Updated FDA Authorization To Sell COVID Antibody On Commercial Market

 
• By Sarah Karlin-Smith

Biden administration will run out of supply of Lilly’s covid antibody bebtelovimab in August, forcing a shift to commercial market due to lack of funds. The transition will require changes to the emergency use authorization and involve a price hike.

Lilly office building
Dwindling government COVID funds shifts Lilly antibody sales to commercial market • Source: Shutterstock

More from United States

More from North America